Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"$84.0 million","newsHeadline":"Advanz Pharma Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$96.0 million","upfrontCash":"$96.0 million","newsHeadline":"Advanz Pharma Corp. Limited Closes Acquisition of the Rights to a Portfolio of Alprostadil Products from UCB S.A. for $83 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Alprostadil

    Menu

    Alprostadil

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              UCB Pharma S.A

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Advanz Pharma Corp. Limited Closes Acquisition of the Rights to a Portfolio of Alprostadil Products from UCB S.A. for $83 Million

              Details:

              Advanz get the rights to a portfolio of alprostadil products including, Prostavasin, Viridal, Vasaprostan and Edex, which consists of injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease, in 20 countries.

              Lead Product(s): Alprostadil

              Therapeutic Area: Psychiatry/Psychology Product Name: Prostavasin

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Advanz Pharma

              Deal Size: $96.0 million Upfront Cash: $96.0 million

              Deal Type: Acquisition April 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              UCB Pharma S.A

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Advanz Pharma Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products

              Details:

              The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.

              Lead Product(s): Alprostadil

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Advanz Pharma

              Deal Size: $98.0 million Upfront Cash: $84.0 million

              Deal Type: Agreement March 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Cayman Alprostadil RM
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Close
              4
              Post Enquiry
              POST ENQUIRY